Adenocarcinoma: all 1,996 studies

Page 13 of 20. Open to participants first (369), then studies with results posted, then the rest; newest registration first within each.

• Pilot Study of a Multimodal Prehabilitation Pancreatic Cancer ProgramStatus unknownNCT03865875Not applicable
• A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody, for Advanced Solid Tumors or With mXELOX/XELOX as First-line Therapy for Advanced Gastric or GEJ AdenocarcinomaCompletedNCT03852251Phase 1/2
• A Prospective Translational Tissue Collection Study in Early and Advanced Pancreatic Ductal Adenocarcinoma and Pancreatic Neuroendocrine Tumours to Enable Further Disease Characterisation and the Development of Potential Predictive and Prognostic BiomarkersStatus unknownNCT03840460
• Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial CancerWithdrawnNCT03836157Phase 2
• The Efficacy and Safety of Nab-paclitaxel Plus S-1 in First-line Treatment of Advanced Biliary Tract AdenocarcinomaCompletedNCT03830606Phase 2
• A Study on Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Patients With Advanced Biliary Adenocarcinoma/Hepatocellular CarcinomaStatus unknownNCT03825705Phase 1/2
• Carbon Ions Radiation Therapy for Resectable or Borderline Resectable Pancreas AdenocarcinomaTerminatedNCT03822936Phase 2
• High Resolution Ultrasound in Pancreatic Ductal AdenocarcinomaActive, not recruitingNCT03820661Not applicable
• Preoperative Chemoradiotherapy for Locally Advanced Resectable Gastric AdenocarcinomaCompletedNCT03814759Phase 2
• A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid TumorsCompletedNCT03811652Phase 1
• Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck CancerTerminatedNCT03809624Phase 1
• A Study of CS1001 in Subjects With Gastric Adenocarcinoma or Gastro-Esophageal Junction AdenocarcinomaCompletedNCT03802591Phase 3
• Albumin-bound Paclitaxel Plus S-1 Versus SOX as First-line Treatment in Advanced or Recurrent Gastric AdenocarcinomaStatus unknownNCT03801668Phase 3
• Survival and Description of Care for Patients With Degenerate Vaterian AmpullomaStatus unknownNCT03800212
• A Study of Personalized Neoantigen Cancer VaccinesCompletedNCT03794128
• General Tissue Response Classification System After ChemotherapyStatus unknownNCT03791268
• A Multi-center, Single-arm, Open, Phase I/IIa Clinical Trial to Evaluate the Efficacy and Safety of EBViNT Cell (EBV Specific Autologous CD8+ T Cell) in Patients With Treatment Failed Epstein Barr Virus (EBV)-Positive MalignanciesStatus unknownNCT03789617Phase 1/2
• Apatinib Combined With POF for Second-line Treatment of Gastric AdenocarcinomaStatus unknownNCT03788174Phase 2
• EUS-guided Laser Ablation in Pancreatic AdenocarcinomaTerminatedNCT03784417Not applicable
• TACE(Transcatheter Arterial Chemoembolization ) Associated With Systemic Chemotherapy Versus Systemic Chemotherapy Alone in Patients With Unresectable CRLM(Colorectal Liver Metastases)Status unknownNCT03783559Phase 3
• CCRO044: Quality of Life Assessments Associated With a Physician Communication Intervention for Prostate Cancer PatientsCompletedNCT03780023
• Study of Gemcitabine Plus Nab-paclitaxel Versus S1 Plus Nab-paclitaxel in Metastatic Adenocarcinoma of the PancreasStatus unknownNCT03779464Phase 2
• Pre-operative Stereotactic Body Radiation Therapy for Pancreatic Adenocarcinoma With or Without CCX872-BWithdrawnNCT03778879Phase 1/2
• Association of Radiochemotherapy and Immunotherapy for the Treatment of Unresectable Oesophageal caNcerCompletedNCT03777813Phase 2
• EUS-RFA for Unresectable Pancreatic Ductal AdenocarcinomaCompletedNCT03772756Not applicable
• Effects of Different Genetic Mutations on Prognosis in sMPLC Adenocarcinoma PatientsStatus unknownNCT03764371
• A Study of Entinostat and FOLFOX in Subjects With Pancreatic AdenocarcinomaWithdrawnNCT03760614Phase 1
• Sequential Use of AG and mFOLFIRINOX as Neoadjuvant Chemotherapy for Resectable Pancreatic CancerCompletedNCT03750669Phase 3
• RAmucirumab Combined wIth Standard Nab-paclitaxel and Gemcitabine as First-line Chemotherapy in Patients With Advanced Pancreatic AdenocarcinomaCompletedNCT03745430Phase 1/2
• HPV Integration and Tumorigenesis of Uterine Cervical AdenocarcinomaStatus unknownNCT03742869
• MM-398 and Ramucirumab in Treating Patients With Gastric Cancer or Gastroesophageal Junction AdenocarcinomaWithdrawnNCT03739801Phase 1/2
• A Study to Evaluate the Safety and Effectiveness of ILIxadencel Administered Into Tumors in Combination With Checkpoint Inhibitor (CPI) in Patients With ADvanced CancerTerminatedNCT03735290Phase 1
• Anlotinib Hydrochloride as Second-line Therapy in Elderly Patients With EGFR Wild-type Lung AdenocarcinomaStatus unknownNCT03728374Phase 2
• Vactosertib in Combination with Pembrolizumab in Metastatic Colorectal or Gastric CancerCompletedNCT03724851Phase 1/2
• Regorafenib Combined With Irinotecan as Second-line in Patients With Metastatic Gastro-oesophageal AdenocarcinomasTerminatedNCT03722108Phase 1/2
• Mechanisms of Metabolic and Hormone Action on Plaque Formation in Brain and Carotid Vessels in Patients With Prostate AdenocarcinomaTerminatedNCT03718338
• Evaluation of Ocoxin-Viusid® in Advanced Pancreatic AdenocarcinomaCompletedNCT03717298Phase 2
• Prospective Evaluation of the Role of MRI in the Perioperative Management of Pancreas AdenocarcinomasCompletedNCT03714542Not applicable
• Metformin Plus/Minus Fasting Mimicking Diet to Target the Metabolic Vulnerabilities of LKB1-inactive Lung AdenocarcinomaStatus unknownNCT03709147Phase 2
• Bevacizumab Plus Capecitabin vs S-1 as Maintenance Treatment Following First-line Chemotherapy in the Patients With Advanced Colorectal AdenocarcinomaWithdrawnNCT03708536Phase 3
• Study of the Combination of Apatinib and POFStatus unknownNCT03707639Phase 2
• A Study to Evaluate Safety, Tolerability, and Efficacy Profile of Rivoceranib With Paclitaxel in Advanced Gastric or Gastroesophageal Junction CancerTerminatedNCT03707028Phase 1/2
• An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction AdenocarcinomaWithdrawnNCT03704077Phase 2
• Gemcitabine & Nab-Paclitaxel in Pancreatic Adenocarcinoma With Positive Peritoneal CytologyStatus unknownNCT03703089Phase 1
• High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic CancerWithdrawnNCT03697239Phase 1/2
• Grapiprant (ARY-007) and Pembrolizumab in Patients With Advanced or Metastatic Post-PD-1/L1 NSCLC AdenocarcinomaTerminatedNCT03696212Phase 1/2
• A Data Collection Study for Patients With Adenocarcinoma Treated With the MyVaccx Immunotherapy Regimen.CompletedNCT03695835
• A Study of IMMray™ PanCan-d Test for Early Detection of Pancreatic Cancer in High-risk GroupsCompletedNCT03693378
• Application of Intrahepatic Arterial Infusion Chemotherapy for Patients With High Risk of Liver Metastases After Pancreatic Cancer SurgeryStatus unknownNCT03687853Not applicable
• CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC)WithdrawnNCT03682744Phase 1
• Phase II/III of Randomized Controlled Clinical Research on IRE Synchronous Chemotherapy for LAPCCompletedNCT03673137Phase 2/3
• Multi-center, Open-label, Phase 1b Clinical Trial to Evaluate the Safety, Tolerability, and Exploratory Efficacy of TEW-7197 in Combination With FOLFOX in Patients With Metastatic Pancreatic Ductal Adenocarcinoma Who Have Failed First-Line Gemcitabine and Nab-PaclitaxelStatus unknownNCT03666832Phase 1/2
• Pancreaticoduodenectomy in Elderly Pancreatic Ductal Adenocarcinoma PatientsCompletedNCT03659903
• Soy Bread Diet in Improving Immune Function in Participants With Prostate CancerCompletedNCT03654638Phase 2
• Eus-guided Cryothermal Ablation in Stage III Pancreatic AdenocarcinomaWithdrawnNCT03649035Phase 3
• Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)CompletedNCT03648489Phase 2
• Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs. FLOT Plus Nivolumab in Patients With Previously Untreated Advanced or Metastatic Gastric CancerCompletedNCT03647969Phase 2
• The Application of Fluorescence Laparoscopy in the Treatment of Adenocarcinoma of the Esophagogastric JunctionStatus unknownNCT03647540Not applicable
• Investigation of the Contents and Prognostic Values of Glucose Metabolism Molecules in Patients With Lung AdenocarcinomaStatus unknownNCT03641105
• A Study of a Personalized Neoantigen Cancer VaccineCompletedNCT03639714Phase 1/2
• Study of Anlotinib Plus Chemotherapy as the First-line Treatment in Patients With Advanced NSCLCStatus unknownNCT03636685Phase 1/2
• Second-line Study of PEGPH20 and Pembro for HA High Metastatic PDACStatus unknownNCT03634332Phase 2
• Efficacy Evaluation of Sequential Treatment With AG and Modified Folfirinox in Metastatic Pancreatic AdenocarcinomaStatus unknownNCT03633734Phase 1/2
• Neoadjuvant Chemoradiation Plus PD-1 Antibody(SHR-1210) in Locally Advanced Proximal Stomach AdenocarcinomaStatus unknownNCT03631615Phase 2
• Prehabilitation of Patients With oEsophageal Malignancy Undergoing Peri-operative TreatmentStatus unknownNCT03626610Not applicable
• Observatory of Patients With Metastatic ProstAte Adenocarcinoma That is Resistant to Castration and Multi-LinE StrategiesActive, not recruitingNCT03611686
• Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal MesotheliomaTerminatedNCT03608618Phase 1
• Predictive Factors of Disease-free Survival After Complete Pathological Response to Neoadjuvant Radiotherapy in Rectal AdenocarcinomaCompletedNCT03601689
• XELOX Combined With Apatinib as Post-operative Chemotherapy in Locally Advanced Gastric AdenocarcinomaStatus unknownNCT03599778Phase 1/2
• Epacadostat and Pembrolizumab Before Surgery in Treating Participants With Stage II-III Esophageal or Gastroesophageal CancerWithdrawnNCT03592407Phase 2
• A Phase I/II Study of OBI-3424 in Subjects with Advanced Solid TumorsTerminatedNCT03592264Phase 1/2
• A Study of Anlotinib in Recurrent/Metastatic Head and Neck AdenocarcinomasStatus unknownNCT03591666Phase 2
• Next Generation Sequencing of Tumor Cells in Locally Advanced Pancreatic AdenocarcinomaCompletedNCT03578939
• Could a Preoperative Feeding Jejunostomy Decrease Sarcopenia for Patients With Oesogastric Adenocarcinoma ?Status unknownNCT03574116
• Prostate Radiotherapy Comparing Moderate and Extreme Hypo-fractionation (PRIME Trial)Active, not recruitingNCT03561961Not applicable
• Evaluation of Ocoxin®-Viusid® in Metastatic Colorectal AdenocarcinomaCompletedNCT03559543Phase 2
• Locally Advanced or Metastatic Pancreatic AdenocarcinomaCompletedNCT03559348Phase 2
• Role of Low Inferior Mesenteric Artery Ligation During Laparoscopic Surgery for Rectosigmoid CancerCompletedNCT03557528
• Evaluation of Oncoxin-Viusid® in Cervical Cancer and Endometrial Adenocarcinoma.CompletedNCT03540407Phase 2
• Trial of Carbon Ion Versus Photon Radiotherapy for Locally Advanced, Unresectable Pancreatic CancerWithdrawnNCT03536182Phase 3
• Siewert Type I-II: CT, PET-CT, EUS Sensitivity/Specificity for the Assessment of Lymph Node MetastasesCompletedNCT03529968
• Scheduling Nab-paclitaxel With GemcitabineCompletedNCT03529175Phase 2
• FOLFIRI Alternate With FOLFOX in Untreated Metastatic Gastric and Esophageal AdenocarcinomaTerminatedNCT03528876Phase 2
• A Study of Nal-IRI With 5-FU, Levofolinic Acid and Oxaliplatin in Patients With Resectable Pancreatic CancerStatus unknownNCT03528785Phase 2
• A Study of IMAB362 in Japanese Subjects With Locally Advanced or Metastatic Gastric or Gastro-esophageal Junction (GEJ) AdenocarcinomaCompletedNCT03528629Not applicable
• Prestoma-Trial for Parastomal Hernia PreventionTerminatedNCT03527784Not applicable
• DCLK1 as a Marker/Indicator of Stem Cell Response in Barrett's Esophagus/Esophageal AdenocarcinomaCompletedNCT03526328
• Short Course Radiotherapy for Localized Prostate CancerCompletedNCT03518853Not applicable
• Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid TumorsTerminatedNCT03511222Phase 1
• Phase 1 Dose Escalation Study of CGX1321 in Subjects With Advanced Gastrointestinal TumorsStatus unknownNCT03507998Phase 1
• Short-course Radiation Followed by mFOLFOX-6 Plus COMPOUND 2055269 for Locally-advanced Rectal AdenocarcinomaActive, not recruitingNCT03503630Phase 2
• F18 DCFPyL PET/CT in Imaging Participants With Recurrent Prostate CancerNo longer availableNCT03501940
• Perioperative mFOLFOX Plus Pembrolizumab in Gastroesophageal Junction (GEJ) and Stomach AdenocarcinomaActive, not recruitingNCT03488667Phase 2
• Gefitinib and Berberine in the First-line Treatment of Lung Adenocarcinoma With EGFR MutationStatus unknownNCT03486496Phase 2
• Ischemic Heart Disease in Male With Prostate AdenocarcinomaStatus unknownNCT03474835Not applicable
• The βIG-H3 Protein: a New Marker in PANCreatic Adenocarcinoma (BIGHPANC)Status unknownNCT03472716
• Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Patients With Advanced Digestive System NeoplasmsStatus unknownNCT03468244Not applicable
• Stereotactic Body Radiation Therapy, Tremelimumab and Durvalumab in Treating Participants With Recurrent or Metastatic Cervical, Vaginal, or Vulvar CancersCompletedNCT03452332Phase 1
• The FLOT Regimen Conversion Therapy of Adenocarcinoma of the Stomach / GastroesophagealStatus unknownNCT03451942Phase 2
• A Study of SLC-0111 and Gemcitabine for Metastatic Pancreatic Ductal Cancer in Subjects Positive for CAIXTerminatedNCT03450018Phase 1/2

← Adenocarcinoma overview